Leishmaniasis (Kala-Azar) (Infectious Disease) – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis – Drugs In Development, 2021, provides an overview of the Leishmaniasis (Infectious Disease) pipeline landscape.Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Leishmaniasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Leishmaniasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 14, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3, 16 and 10 molecules, respectively.

Leishmaniasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Leishmaniasis (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Leishmaniasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

ABIONYX Pharma SA

Acea Biotech Inc

Biokawthar Technologies SAS

BioLingus AG

Daiichi Sankyo Co Ltd

DetectoGen Inc

Eisai Co Ltd

GlaxoSmithKline Plc

Immune Modulation Inc

Impetis Biosciences Ltd

Macrophage Therapeutics Inc

ManRos Therapeutics

Matinas BioPharma Holdings Inc

MedC Biopharma Ltd

Mind Medicine MindMed Inc

Molecular Targeting Technologies Inc

Mycosynthetix Inc

NanoCliq LLC

Nanomerics Ltd

Novartis AG

Oblita Therapeutics BVBA

Pai Life Sciences Inc

Pfizer Inc

Pharos I&BT Co Ltd

Rakta Therapeutics Inc

Satellos Bioscience Inc

Synstar Japan Co Ltd

Table of Contents

Table of Contents

Introduction

Leishmaniasis (Kala-Azar) - Overview

Leishmaniasis (Kala-Azar) - Therapeutics Development

Leishmaniasis (Kala-Azar) - Therapeutics Assessment

Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development

Leishmaniasis (Kala-Azar) - Drug Profiles

Leishmaniasis (Kala-Azar) - Dormant Projects

Leishmaniasis (Kala-Azar) - Discontinued Products

Leishmaniasis (Kala-Azar) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Products under Development by Universities/Institutes, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Leishmaniasis (Kala-Azar) – Pipeline by ABIONYX Pharma SA, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Acea Biotech Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Biokawthar Technologies SAS, 2021

Leishmaniasis (Kala-Azar) – Pipeline by BioLingus AG, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Daiichi Sankyo Co Ltd, 2021

Leishmaniasis (Kala-Azar) – Pipeline by DetectoGen Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Eisai Co Ltd, 2021

Leishmaniasis (Kala-Azar) – Pipeline by GlaxoSmithKline Plc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Immune Modulation Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Impetis Biosciences Ltd, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Macrophage Therapeutics Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by ManRos Therapeutics, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Matinas BioPharma Holdings Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by MedC Biopharma Ltd, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Mind Medicine MindMed Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Molecular Targeting Technologies Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Mycosynthetix Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by NanoCliq LLC, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Nanomerics Ltd, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Novartis AG, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Oblita Therapeutics BVBA, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Pai Life Sciences Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Pfizer Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Pharos I&BT Co Ltd, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Rakta Therapeutics Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Satellos Bioscience Inc, 2021

Leishmaniasis (Kala-Azar) – Pipeline by Synstar Japan Co Ltd, 2021

Leishmaniasis (Kala-Azar) – Dormant Projects, 2021

Leishmaniasis (Kala-Azar) – Dormant Projects, 2021 (Contd..1)

Leishmaniasis (Kala-Azar) – Dormant Projects, 2021 (Contd..2)

Leishmaniasis (Kala-Azar) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Leishmaniasis (Kala-Azar), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports